The Arising Sampler

Menopause Hormone Therapy Linked to Greater Semaglutide Weight Loss in Midlife Women

Midlife women who took menopause hormone therapy while on Tsemaglutide lost more weight than those who did not, according to The Menopause Society's report of a new study. The finding is an association, and the lead researcher says it is too early to act on it.

his article is based on that report. The study paper itself was not reviewed.

The question matters because of who is using these drugs. According to the Society, about one in five women aged 50 to 64 report current or past use of a GLP-1 obesity medication. That is the highest share of any demographic group in the U.S. The report notes that weight gain at midlife is common. It says the gains are largely driven by aging, though menopause-related factors can contribute to fat accumulation and redistribution.

Menopause Hormone Therapy Linked to Greater Semaglutide Weight Loss in Midlife Women

1

Falling Cardiolipin Levels May Explain Why Aging Muscles Lose Power

2

Swedish 47-Year Study: Aerobic Fitness and Endurance Peak Between 26 and 36

3

Gene SRSF1 Made Aged Cells Look Younger; Linked to Longer Mouse Life

4

Scans of 100,000 Patients Link Active Brown Fat to Better Metabolic Health

5

According to the report, the study was a retrospective observational cohort. It included nearly 2,400 women taking semaglutide and nearly 1,500 taking tirzepatide. All were over 45 with a body mass index above 27. The researchers concluded that hormone therapy was associated with significantly greater and sustained weight loss with semaglutide.

Tirzepatide told a different story. Women using hormone therapy lost more weight at first. By the end, the difference did not reach statistical significance, according to the report. In plain terms, the gap was too small or too uncertain to rule out chance. The report gives no figures for how much extra weight the hormone users lost.

The design limits what the result can say. A retrospective study looks back at records of what women already did. It cannot show that hormones caused the extra weight loss. Women who use hormone therapy may differ from those who do not in ways that also affect weight. That is a general caution about this kind of study, not a finding from the report.

Lead author Dr. Regina Castaneda of Mayo Clinic Florida called the signal consistent with earlier, smaller studies. She said it is biologically plausible, citing preclinical data that suggest estrogen and GLP-1 signaling may work together. She also noted the effect was stronger with semaglutide than tirzepatide, which she said deserves further study.

She was direct about the limits. According to the report, she said: "it is too early to draw firm conclusions." She added that the findings need confirmation in well- designed prospective trials. She also said weight loss is not an indication for menopause hormone therapy.

That is the main takeaway for women on a GLP-1. This result does not support starting hormones to lose weight. Dr. Stephanie Faubion, the Society's medical director, said more research is needed. She said the study highlights the value of considering menopause-specific factors in personalized weight management. Readers should not start or stop hormone therapy or a GLP-1 medication without talking to their clinician first.

The full results will be presented at The Menopause Society's 2026 Annual Meeting in San Diego, October 20–24. The next test is a prospective trial that compares women on a GLP-1 with and without hormone therapy.

Source: The Menopause Society

Sources and further reading: menopause.org/press-releases/hormone-therapy-may-increase-weight-loss-effectiveness-of-glp-1s

THE ARISING · LONGEVITY & HEALTHSPAN

THURSDAY, OCTOBER 15, 2026

IN THIS EDITION · LONGEVITY & HEALTHSPAN

LONGEVITY & HEALTHSPAN · STANDARD READ · 2 MIN

NATURE AGING · 2 SOURCES

Falling Cardiolipin Levels May Explain Why Aging Muscles Lose Power

Aging muscle has a puzzle at its core: as mitochondria, the cell's Tenergy units, work less well, muscle shifts toward fibers that rely on them more. A new study in Nature Aging suggests a single fat in the mitochondrial membrane, called cardiolipin, may explain why.

he evidence comes mainly from mice, with some work in human muscle. It is a peer-reviewed paper published in 2026 by a large team, led by Fabian Finger and Zachary Gerhart-Hines at the University of Copenhagen, according to Earth.com's coverage. We could review only the abstract, which does not give the number of animals or people studied. Anything beyond the abstract below is attributed to Earth.com.

According to the abstract, aging brings two changes that seem to conflict. Mitochondrial function in skeletal muscle declines. Yet muscle composition shifts toward fibers rich in mitochondria. The authors report that cardiolipin links the two. Its levels fall in aging mouse and human muscle.

To test cause, the researchers lowered cardiolipin in young mice. They deleted a gene called Crls1, which makes an enzyme needed to build the fat, only in muscle and only on cue. This reproduced key hallmarks of aging, including a shift from glycolytic fibers to oxidative ones. Glycolytic fibers burn sugar quickly. Earth.com describes them as the fast, powerful fibers.

Menopause Hormone Therapy Linked to Greater Semaglutide Weight Loss in Midlife Women

1

Falling Cardiolipin Levels May Explain Why Aging Muscles Lose Power

2

Swedish 47-Year Study: Aerobic Fitness and Endurance Peak Between 26 and 36

3

Gene SRSF1 Made Aged Cells Look Younger; Linked to Longer Mouse Life

4

Scans of 100,000 Patients Link Active Brown Fat to Better Metabolic Health

5

The abstract also describes how the shift happens. Mitochondria send a signal to the cell nucleus through a protein called estrogen-related receptor γ. That signal promotes sugar uptake that is sensitive to reactive oxygen species, which are damaging byproducts of energy production. It also reroutes sugar to support the cell's antioxidant defenses.

Some of the damage was also reversible in the mice. When the authors restored Crls1 in adult mice that had lost it, cardiolipin levels returned, muscle atrophy began to reverse and premature death was fully rescued, according to the abstract. The abstract does not say whether the fiber-type shift itself reversed.

Earth.com reports a result that the abstract does not describe. Cardiolipin-depleted mice given the antioxidant N-acetylcysteine for eight weeks ended up with smaller muscles, not healthier ones. Finger told Earth.com: "The fiber switch is not the muscle failing, but the muscle trading power for protection." Earth.com says these groups were small, with three to six mice each.

That is the basis for the question many readers will ask about antioxidant pills. The study does not answer it. The mice had been engineered to lack cardiolipin, and the study did not test supplements in older people. Earth.com also notes that the human data were limited to stored muscle samples from nine men, which showed only that cardiolipin was lower with age. Readers should not start or stop any supplement or medication without talking to their clinician.

The same goes for exercise. The abstract does not mention training, so we cannot say whether building power slows this fiber shift. What the study does suggest is that the loss of powerful fibers may have a specific biological cause. That makes the cause a possible target for future treatments. It is not yet a guide to what anyone should do.

Earth.com reports that the authors' next step is to raise cardiolipin in naturally old mice and see whether that protects their muscles. That result will show whether this pathway matters beyond a model of early muscle aging.

Sources: Nature aging (2026), Earth.com (reporting on a University of Copenhagen study in Nature Aging)

Sources and further reading: doi.org/10.1038/s43587-026-01227-7 · www.earth.com/science/aging-muscles-may-be-sacrificing-strength-to-protect-themselves/

THE ARISING · LONGEVITY & HEALTHSPAN

THURSDAY, OCTOBER 15, 2026

IN THIS EDITION · LONGEVITY & HEALTHSPAN

LONGEVITY & HEALTHSPAN · STANDARD READ · 3 MIN

JOURNAL OF CACHEXIA, SARCOPENIA AND MUSCLE · 2

SOURCES

Swedish 47-Year Study: Aerobic Fitness and Endurance Peak Between 26 and 36

Physical capacity in ordinary adults appears to peak between the mid- 20s and mid-30s and then slowly fall, according to a 47-year Swedish study in the Journal of Cachexia, Sarcopenia and Muscle. Strength was not tracked across the decades; the study followed aerobic capacity, muscular endurance and leg power, with grip strength measured only at 63. Press coverage describes the finding as 'fitness and strength' declining around 35, but the paper's peaks range from 26 to 36.

Menopause Hormone Therapy Linked to Greater Semaglutide Weight Loss in Midlife Women

1

Falling Cardiolipin Levels May Explain Why Aging Muscles Lose Power

2

Swedish 47-Year Study: Aerobic Fitness and Endurance Peak Between 26 and 36

3

Gene SRSF1 Made Aged Cells Look Younger; Linked to Longer Mouse Life

4

Scans of 100,000 Patients Link Active Brown Fat to Better Metabolic Health

5

Photo: “Top Track - Great Field Halloween parkrun” by dorsetbays, CC BY-SA 2.0

This is an observational study in people. It followed 427 individuals (48% women), all born in 1958 and randomly selected as 16-year-old pupils in 1974 to represent Swedish adolescents. They were tested at ages 16, 27, 34, 52 and 63. An observational study can describe a pattern. It cannot prove what causes it.

The team measured aerobic capacity, which is how well the body uses oxygen during effort. They estimated it with a submaximal cycle test. At age 16 they converted a 9- minute run result instead. They also measured muscular endurance with bench press repetitions, and leg power with a standing jump test.

Estimated aerobic capacity and muscular endurance peaked between ages 26 and 36 in both sexes. The decline then began at 0.3% to 0.6% per year. By age 63 it had sped up to 2.0% to 2.5% per year, according to the paper.

Total (absolute) aerobic capacity peaked at 35 in women and 36 in men. From that peak to age 63, it fell by 30% in women and 33% in men. Aerobic capacity adjusted for body weight peaked earlier in men (age 26) than in women (age 31). From about age 40, the rate of decline was similar in both sexes.

People also drifted apart over time. The spread in absolute aerobic capacity between individuals grew fivefold from age 16 to 63. At 63, no men and four women fell below the European cut-offs for low grip strength or slow chair stands, which are used to flag sarcopenia, the age-related loss of muscle. Decline in the group, then, did not mean disease for most people.

The authors say the pattern matches what is seen in elite athletes, who tend to peak around 35 even while training. They conclude that a decline in physical capacity can be seen before age 40. They add that it can later lead to clinically significant physical

problems, especially in people with a sedentary lifestyle. That is their interpretation of the pattern, not something the study tested directly.

The press coverage went further on exercise. ScienceDaily, relaying a Karolinska Institutet release, reports that average performance at 63 was roughly 30% to 48% below peak. It also reports that people who became active in adulthood improved their capacity by about 5% to 10%. Those figures come from that coverage, not from the parts of the paper reviewed here. ScienceDaily quotes lead author Maria Westerståhl: "It is never too late to start moving. Our study shows that physical activity can slow the decline in performance, even if it cannot completely stop it."

A separate paper from the same cohort, in Scientific Reports in 2026, looked at the heart and blood vessels. Higher aerobic capacity at 34 and at 52 predicted less arterial stiffness at 63, a marker of cardiovascular risk. The link held after accounting for obesity, smoking, blood pressure and cholesterol measures. The design is observational. The authors' wording leans toward cause, suggesting that maintaining aerobic capacity from early adulthood can reduce arterial stiffness and cardiovascular risk, but the data show an association. The press coverage says plainly that the results do not establish that better fitness directly prevented arterial stiffening.

There are limits. The cohort is a single birth year from one country. The study says

people with a university degree or an active youth were more likely to keep taking part, though the analysis included everyone from the start to reduce that bias. Activity was recorded with a simple yes-or-no question. Aerobic capacity was estimated, not directly measured. The study also describes group averages, so no one should treat 35 as a personal deadline.

The authors say their next step is to look for the biological mechanisms behind the early peak and behind exercise's partial protection.

Sources: Journal of cachexia, sarcopenia and muscle (2025), ScienceDaily (Karolinska Institutet; Journal of Cachexia, Sarcopenia and Muscle)

Sources and further reading: doi.org/10.1002/jcsm.70134 · www.sciencedaily.com/releases/2026/10/261014000912.htm

THE ARISING · LONGEVITY & HEALTHSPAN

THURSDAY, OCTOBER 15, 2026

IN THIS EDITION · LONGEVITY & HEALTHSPAN

LONGEVITY & HEALTHSPAN · STANDARD READ · 2 MIN

NATURE AGING · 2 SOURCES

Gene SRSF1 Made Aged Cells Look Younger; Linked to Longer Mouse Life

Turning up a single gene made aged human skin cells look and behave Tmore like young ones, and in old mice it was linked to slower decline and a longer median life, according to a new study in Nature Aging. The lifespan finding is an association, not proof that the gene extends life, and the mouse groups were small.

his is early evidence. The work combines experiments in cultured human cells with tests in worms and mice. The mouse lifespan result came from small groups of 9 to 10 animals each. It is not a human trial, and nothing here shows a benefit for people.

The gene is SRSF1. It makes a protein that helps process RNA, the working copies of genes that cells read to build proteins. Plesa, Jung and colleagues first built a "transcriptomic age" predictor in human fibroblasts, a common type of skin cell. The predictor reads which genes are switched on and off and estimates how old the cells are.

They then ran a screen. They added many different genes to aged cells using a cDNA overexpression approach, and checked which ones shifted the cells toward a younger gene-activity pattern. SRSF1 came out as the standout. The abstract does not say how the screen was laid out in detail.

Menopause Hormone Therapy Linked to Greater Semaglutide Weight Loss in Midlife Women

1

Falling Cardiolipin Levels May Explain Why Aging Muscles Lose Power

2

Swedish 47-Year Study: Aerobic Fitness and Endurance Peak Between 26 and 36

3

Gene SRSF1 Made Aged Cells Look Younger; Linked to Longer Mouse Life

4

Scans of 100,000 Patients Link Active Brown Fat to Better Metabolic Health

5

Why does this matter? Earlier attempts to turn back cellular age used Yamanaka factors, a set of genes that can reset cells. According to the paper, toxicity and efficacy concerns limit their use in living animals. The authors report that SRSF1 produced youthful gene-activity patterns without the cells losing their identity. A skin cell stayed a skin cell.

In cultured cells, switching on SRSF1 reduced senescence, which is when cells stop dividing and linger in a damaged state. It also reduced proteostatic stress, meaning strain on the cell's system for handling proteins, and inflammatory signaling.

In aged mice, inducible SRSF1 expression reduced frailty progression by 44%. It was also associated with a 14% longer median lifespan. Median lifespan is the age by which half the animals have died. The abstract uses the word "associated" for lifespan, and that caution is worth keeping. With 9 to 10 mice per group, chance can play a large role. This is the weakest part of the argument.

Only the abstract was available to us, and the full paper is behind a paywall. So we cannot say how the gene was delivered, how much was used, whether results differed between male and female mice, or whether there were side effects. The abstract also does not explain how SRSF1 produces its effects.

FOR YOU

For personal health, our reading is cautious: this study gives no basis for splicing- related supplements or tests today. Cells in a dish and mice are a long way from a safe, proven treatment for people. Any therapy would also need a way to deliver the gene safely and at the right dose. The abstract does not address either point. Do not start or stop any medication, treatment or supplement without consulting your clinician.

The authors call SRSF1 "a promising geroprotective target", meaning a possible route to protecting against aging. That is a reasonable description of where things stand. What to watch next: larger animal studies, independent replication, and the first safety data on any approach that changes SRSF1 activity.

Sources: Nature Aging (2026), Nature Aging (publisher page)

Sources and further reading: doi.org/10.1038/s43587-026-01234-8 · www.nature.com/articles/s43587-026-01234-8

THE ARISING · LONGEVITY & HEALTHSPAN

THURSDAY, OCTOBER 15, 2026

IN THIS EDITION · LONGEVITY & HEALTHSPAN

LONGEVITY & HEALTHSPAN · STANDARD READ · 3 MIN

NATURE · 2 SOURCES

Scans of 100,000 Patients Link Active Brown Fat to Better Metabolic Health

People who carry active brown fat tend to have healthier blood sugar, Tcholesterol and hearts. A large new analysis suggests they may also have lower rates of psychiatric disease. But the finding shows a link, not a cause, and it does not mean anyone should start a blood pressure drug to get more of this tissue. Do not start, stop or change losartan, other blood pressure drugs of its class, SSRIs or any medication without talking to your clinician.

he work was published in Nature in 2026. It is an observational study in people, not a trial. Researchers drew on a cohort of 101,243 patients at a large cancer centre. They also ran a proof-of-concept test of the drug losartan, which the study reports increased brown fat cell activity and whole-body energy expenditure. Observational data can show that two things go together. They cannot show that one causes the other.

Brown fat is different from the white fat that stores energy. According to the study's abstract, brown adipose tissue uses energy to produce heat. Earlier work had linked detectable brown fat in humans to a lower prevalence of cardiometabolic disease, meaning conditions that affect the heart and metabolism. What was missing, the authors write, was a full picture of which health conditions it relates to, and a fast way to measure how active the tissue is in many people.

Menopause Hormone Therapy Linked to Greater Semaglutide Weight Loss in Midlife Women

1

Falling Cardiolipin Levels May Explain Why Aging Muscles Lose Power

2

Swedish 47-Year Study: Aerobic Fitness and Endurance Peak Between 26 and 36

3

Gene SRSF1 Made Aged Cells Look Younger; Linked to Longer Mouse Life

4

Scans of 100,000 Patients Link Active Brown Fat to Better Metabolic Health

5

The team used big data and artificial intelligence to fill that gap. In an unbiased sweep across all diagnoses, cardiovascular and psychiatric diseases were less prevalent in people with brown fat. Then a machine learning approach semi- automatically measured brown fat activity in about 8,700 patients.

Higher activity was tied to lower odds of cardiometabolic disease and to a healthier distribution of white fat. This was especially true for brown fat in the axillary depot, the area around the armpit. People with brown fat also had more favourable blood sugar measures, lipid profiles, inflammatory markers and echocardiographic indices, which are measures taken from heart ultrasound.

The medication analysis produced the headline-friendly result. Use of angiotensin receptor blockers, a class of blood pressure drugs, was positively associated with having brown fat. As a proof of concept, the authors showed that one of them, losartan, increased brown fat cell activity and whole-body energy expenditure.

Here the coverage goes further than the abstract. News-Medical, summarising a Rockefeller University release, reports that the energy findings came from experiments in cultured cells and in healthy mice, which kept a steady body weight. It also quotes first author Nicolás Gómez-Banoy saying losartan acts on brown fat through different molecular pathways than its blood pressure effect. That could, he says, allow future therapies to stimulate brown fat in people with normal blood pressure. The abstract does not give those details, so they should be read as the researchers' view, not settled fact.

That is why the drug link is not a reason to take losartan. The human data show only that people on these drugs were more likely to have brown fat. They do not show that the drug created it, or that taking it would improve anyone's health. Losartan is a prescription medicine for people with a medical need. The study frames its result as a platform for drug repurposing, not as a recommendation.

The mental health finding also needs care. Gómez-Banoy told News-Medical that metabolically healthy people tend to have lower rates of psychiatric disease, so brown fat may simply track with better metabolic health. The coverage also reports that SSRI antidepressants were associated with dampened brown fat activity, and that the researchers want to look at possible downsides, including osteoporosis and skin disease. None of those points is in the abstract. Anyone taking an SSRI should not read this as a reason to change treatment.

Other limits matter too. The patients were being monitored for cancer, so they may not represent the general public. This is also where the argument is weakest: an association in a single hospital cohort cannot say whether brown fat improves health, whether it is a marker of it, or whether drugs shape it. The abstract does not settle these questions, so they remain open.

For now, the practical message is modest. Brown fat looks like a marker of metabolic health, and this study gives researchers a way to measure it at scale. Watch for work that tests whether activating brown fat in people improves health outcomes, and whether other drugs flagged in the data do the same. Senior author Paul Cohen told News-Medical, "This is just a start."

Sources: Nature (2026), News-Medical (Rockefeller University release; study in Nature)

Sources and further reading: doi.org/10.1038/s41586-026-11162-7 · www.news-medical.net/news/20261014/Common-blood-pressure-drug-boosts-brown-adipose-tissue-activity-and-metabolism.aspx

A R I S I N G H E A L T H / H E A L T H I N T E L L I G E N C E

HEALTH & LONGEVITY / FEATURE 06 OF 15

Night Shifts, Meal Timing and Glucose Variability

Wearable data from 72 Swiss hospital workers offer a closer look at what happens

to metabolic signals when the clock is inverted.

A study published in npj Biological Timing and Sleep followed 72 Swiss hospital shift workers across

three night shifts and three day shifts. The researchers combined wearable measurements with

app-based information about food intake and physiological signals. The original brief reports lower

caloric intake during night shifts, but greater glucose variability and higher post-meal glucose

excursions. Cortisol and heart-rate measures also changed.

This is an important distinction: total calories and glucose stability are not interchangeable. A person

may eat less over a shift and still experience larger swings in glucose. Circadian timing, sleep

disruption, stress, meal composition and physical activity could all contribute. The brief describes

exploratory associations between nighttime eating and glucose variability; it does not establish that

moving a meal would necessarily prevent the changes.

The clinical appeal is obvious. Shift workers represent a large population for whom standard advice

about breakfast, dinner and sleep is difficult to implement. Continuous sensing may reveal patterns

that a fasting blood test misses. But an observational comparison across work schedules cannot

identify a single causal mechanism or establish long-term diabetes risk from a few nights of

measurements.

For patients, the actionable message is not to chase every glucose fluctuation. Consistent sleep

opportunities, sensible meal planning and management of established cardiometabolic risk factors

remain more defensible than a universal nighttime fasting rule. A future randomized study could test

whether changing meal timing improves clinically meaningful outcomes in shift workers.

EVIDENCE / SOURCE CONTEXT

npj Biological Timing and Sleep (2026-09-29); observational study, 72 shift workers.

Expanded editorial analysis from a source brief; independent primary-source verification pending.

A R I S I N G H E A L T H / H E A L T H I N T E L L I G E N C E

HEALTH & LONGEVITY / FEATURE 07 OF 15

Strength, Nutrition and Survival in Older Adults

A 16-year Japanese cohort suggests two simple domains deserve attention together:

muscular strength and nutritional status.

In the Journal of Cachexia, Sarcopenia and Muscle, investigators followed 1,065 Japanese adults aged

70 and older for 16 years. The supplied research brief reports 415 deaths during follow-up. Lower

leg-press strength and poorer nutritional status were each independently associated with higher

mortality.

The strength of this finding is its long follow-up and its focus on outcomes that matter to people, not

merely a laboratory biomarker. Leg strength is closely tied to rising from a chair, climbing stairs and

recovering from a stumble. Nutritional status, meanwhile, can influence resilience during illness and

the ability to sustain muscle. Their independent associations suggest neither domain should be

overlooked.

There is an equally important limit. This is observational research. Lower strength or poor nutrition

could be markers of underlying disease, frailty, socioeconomic conditions or other factors that also

affect survival. The study does not prove that a leg-press program or a particular supplement would

extend life, and the brief does not provide adjusted hazard ratios or intervention details.

For clinicians and patients, the sensible next question is whether assessment can identify people who

would benefit from established resistance training, adequate dietary protein, nutrition evaluation or

physical therapy. The most useful future trial would test a combined program against meaningful

endpoints such as mobility, hospitalization and independence—not simply changes in muscle

measurements.

EVIDENCE / SOURCE CONTEXT

Journal of Cachexia, Sarcopenia and Muscle (2026-10-01); observational cohort, n=1,065.

Expanded editorial analysis from a source brief; independent primary-source verification pending.

A R I S I N G H E A L T H / H E A L T H I N T E L L I G E N C E

HEALTH & LONGEVITY / FEATURE 08 OF 15

Can the Retina Reveal Future Balance Problems?

A Canadian longitudinal study connects retinal vessel measurements with

subsequent balance impairment—but screening utility remains unproven.

A study in Investigative Ophthalmology & Visual Science followed 12,929 Canadian adults aged 45 to

85 for three years. According to the supplied brief, 2,378 developed balance impairment. Wider retinal

venules were associated with greater odds of balance problems, while larger retinal arteriolar area

was associated with lower odds.

The retina is one of the few places where blood vessels can be examined directly without invasive

testing. Researchers have long explored whether retinal vascular patterns reflect systemic vascular or

neurological health. That makes an association with later balance function biologically interesting:

balance depends on coordinated vision, sensory input, muscle function and central nervous system

processing.

However, a risk marker is not automatically a screening test. To justify clinical use, a retinal

measurement would need reproducibility, clear thresholds, meaningful prediction beyond age and

established risk factors, and evidence that acting on the result improves outcomes. The brief does not

supply those performance characteristics.

This study also cannot tell us whether retinal vascular differences cause balance decline or merely

travel with other conditions. For now, fall-risk assessment should remain grounded in symptoms,

medications, vision, gait, strength and other established clinical factors. Independent replication and

predictive validation would be the next milestones.

EVIDENCE / SOURCE CONTEXT

Investigative Ophthalmology & Visual Science (2026); longitudinal observational cohort, n=12,929.

Expanded editorial analysis from a source brief; independent primary-source verification pending.

A R I S I N G H E A L T H / H E A L T H I N T E L L I G E N C E

HEALTH & LONGEVITY / FEATURE 09 OF 15

Augmented-Reality Tai Chi: A Trial Worth Watching, Not a Result

Researchers have proposed a three-arm trial for diabetes-related cognitive

impairment. The outcome is still unknown.

A BMJ Open protocol outlines a planned randomized study of 246 adults aged 45 to 75 with

diabetes-associated cognitive impairment. Participants would be assigned to

augmented-reality-assisted Tai Chi, instructor-led Tai Chi or standard care. The two exercise groups

would train three times per week for 12 weeks, with change in a cognitive test score as the primary

outcome.

The design asks a useful question: can digital guidance make a movement intervention more accessible

or scalable without losing the advantages of human instruction? Tai Chi combines physical activity,

balance, motor sequencing and attention. Augmented reality could offer cues and feedback, potentially

supporting home practice or reducing the need for repeated in-person supervision.

But this is a protocol, not a completed trial. There are no efficacy results to report, no evidence yet that

the augmented-reality version is superior, and no basis for promising cognitive improvement. A trial of

this size may also be underpowered for outcomes such as dementia incidence or long-term

independence.

What should readers watch? Adherence, safety, between-group differences, whether assessors are

blinded, and whether any cognitive changes persist after the 12-week program. A positive finding

would support further testing; it would not, by itself, establish disease modification.

EVIDENCE / SOURCE CONTEXT

BMJ Open (2026-09-30); registered randomized-trial protocol, planned n=246; no results.

Expanded editorial analysis from a source brief; independent primary-source verification pending.

A R I S I N G H E A L T H / H E A L T H I N T E L L I G E N C E

HEALTH & LONGEVITY / FEATURE 10 OF 15

Exercise for Children With Coordination Disorder: Why Certainty Matters

A systematic review of randomized trials finds promising strength signals but

insufficient evidence for broad claims.

A systematic review in Physical & Occupational Therapy in Pediatrics examined ten randomized trials

of exercise interventions for young people with developmental coordination disorder. Some trials

reported short-term improvements in muscle strength or power. The authors rated certainty in those

findings as low, and certainty for cardiorespiratory fitness, speed, agility and lasting activity habits as

very low.

Randomization is valuable, but the label “randomized trial” does not guarantee a reliable answer.

Small samples, differences in intervention type, outcome measurement, follow-up duration and risk of

bias can leave a literature difficult to interpret. In this review, the trials were too heterogeneous for a

meaningful pooled statistical estimate.

The practical challenge is to distinguish a plausible, beneficial activity from an intervention with

demonstrated effects on a specific clinical outcome. Exercise may offer enjoyment, confidence and

opportunities for participation even when the literature cannot yet quantify improvements in fitness.

Conversely, the evidence should not be presented as proving durable motor or cardiovascular benefit.

The next generation of studies needs consistent measures, meaningful follow-up, careful reporting of

harms and adherence, and interventions designed around goals important to children and families. The

broader lesson for longevity medicine is universal: evidence strength depends on more than a

study-design label.

EVIDENCE / SOURCE CONTEXT

Physical & Occupational Therapy in Pediatrics (2026-09-30); systematic review of ten RCTs.

Expanded editorial analysis from a source brief; independent primary-source verification pending.

A R I S I N G H E A L T H / H E A L T H I N T E L L I G E N C E

SCIENCE, TECHNOLOGY & MEDICINE / FEATURE 11 OF 15

Can Machine Learning Improve Colorectal Polyp Triage?

A 4,108-person study tests nine algorithms—and illustrates why modest

discrimination should temper excitement.

Researchers in Wenzhou, China, assessed nine machine-learning approaches using noninvasive

information from 4,108 adults aged 50 to 74 who underwent colonoscopy after initial screening. The

supplied JMIR Medical Informatics brief reports that XGBoost achieved the highest area under the

receiver operating characteristic curve, 0.672. LightGBM was preferred for triage because its recall

was higher, at 0.6503.

These numbers matter. An area under the curve of 0.672 indicates some ability to distinguish

higher-risk from lower-risk people, but it is far from near-perfect classification. Recall describes the

proportion of cases identified by a chosen threshold; it does not reveal the false-positive burden by

itself. The “best” model therefore depends on what clinicians are trying to optimize and what errors

cost.

In colorectal screening, a false negative could delay evaluation, while too many false positives could

overwhelm colonoscopy capacity. A model that performs acceptably in one referral population may

perform differently in a general screening population. The brief does not establish external validation,

calibration, equity across subgroups or prospective impact on patient outcomes.

The opportunity is decision support, not autonomous diagnosis. Before adoption, a system would need

comparison against existing screening pathways, transparent thresholds, prospective testing and

monitoring for unequal performance. For AI in medicine, this is a useful reminder: a machine-learning

result becomes clinically valuable only when it improves a real decision.

EVIDENCE / SOURCE CONTEXT

JMIR Medical Informatics (2026-09-30); cross-sectional model evaluation, n=4,108.

Expanded editorial analysis from a source brief; independent primary-source verification pending.

A R I S I N G H E A L T H / H E A L T H I N T E L L I G E N C E

SCIENCE, TECHNOLOGY & MEDICINE / FEATURE 12 OF 15

CT Scans as Muscle Assessments: The Promise of Opportunistic AI

A cancer-imaging model combines radiology and clinical data to identify sarcopenia,

potentially extracting new value from existing scans.

A study in the Journal of Cachexia, Sarcopenia and Muscle developed a model combining clinical

variables, CT image features and deep learning to identify sarcopenia in people with gastric cancer.

The supplied brief reports data from 1,067 patients at two centers and an association between

sarcopenia and poorer overall survival. The authors described their identification performance as

accurate, although the brief does not provide numerical discrimination or calibration measures.

This is an example of opportunistic imaging: obtaining a clinically relevant measurement from a scan

already performed for another reason. In cancer care, CT images can contain information about

muscle quantity and distribution. If extraction becomes reliable and inexpensive, clinicians might

identify patients who need nutrition assessment, rehabilitation or closer functional monitoring without

ordering another test.

But identifying a risk state is different from proving that acting on the model changes outcomes.

Cancer stage, treatment intensity, systemic inflammation and baseline health can confound survival

associations. A two-center development sample also does not establish performance across scanners,

institutions, populations or treatment settings.

Before a clinical rollout, ask for independent external validation, calibration, prespecified thresholds,

workflow burden and evidence that model-triggered interventions help patients. The most exciting

prospect is not a prettier CT report; it is earlier, better-targeted supportive care with measured

benefit.

EVIDENCE / SOURCE CONTEXT

Journal of Cachexia, Sarcopenia and Muscle (2026-10-01); two-center model development, n=1,067.

Expanded editorial analysis from a source brief; independent primary-source verification pending.

A R I S I N G H E A L T H / H E A L T H I N T E L L I G E N C E

SCIENCE, TECHNOLOGY & MEDICINE / FEATURE 13 OF 15

The Smart Home as a Health Platform: Opportunity and Uneven Access

A 169-study scoping review shows how sensing and machine learning are entering

everyday environments, while adoption remains concentrated.

A scoping review in JMIR Medical Informatics screened 6,276 records and included 169 studies

published from 2005 through February 2025. The researchers examined sensors, machine learning

and home-based health monitoring, including applications for older adults. The supplied brief notes

that implementation was concentrated in Europe, East and Southeast Asia, and higher-income

countries.

The appeal is easy to understand. Home-based systems might track movement patterns, changes in

routine or signals suggesting increased risk. Unlike episodic office visits, ambient sensing can reveal

changes over days and weeks. That creates opportunities for earlier conversations about falls,

functional decline and support needs.

The challenges are equally substantial. Privacy, consent, false alarms, accessibility, connectivity,

caregiver burden and the dignity of being monitored must be designed into the product. A scoping

review maps a field; it does not prove that a given system reduces hospitalizations, prevents falls or

allows people to live independently for longer.

For Arising Health, the strategic implication is that technology should disappear into useful care. A

meaningful platform would provide clear explanations, actionable summaries and user control over

what is shared. The next evidence threshold is prospective demonstration of outcomes and equitable

deployment—not simply adding more sensors.

EVIDENCE / SOURCE CONTEXT

JMIR Medical Informatics (2026-09-30); scoping review, 169 studies.

Expanded editorial analysis from a source brief; independent primary-source verification pending.

A R I S I N G H E A L T H / H E A L T H I N T E L L I G E N C E

SCIENCE, TECHNOLOGY & MEDICINE / FEATURE 14 OF 15

AI in High-Risk Surgery: Ethics Is Part of Performance

A narrative review asks whether equity and safety receive enough attention when

algorithms enter complex perioperative decisions.

A narrative review in JMIR Perioperative Medicine searched PubMed, Embase, CENTRAL and Scopus

for studies from 2010 through July 2024 concerning artificial intelligence around surgery for seriously

ill patients. The review focused on equity, ethics and safety in populations including people with

cancer, organ failure, frailty, dementia or stroke.

These are settings in which a seemingly small model error can have an outsized effect. A prediction

may influence whether a patient receives an operation, which resources are allocated, or how risks are

communicated. A tool trained on one health system may underperform in another, and a high average

accuracy can conceal poor performance in vulnerable groups.

The supplied brief does not report the review’s detailed findings. It would therefore be inappropriate

to claim that the authors proved a particular bias or measured a specific rate of unsafe deployment.

The review is best understood here as a framework for questions that need answers before adoption.

At minimum, decision-support tools should document intended use, training populations, external

validation, calibration, subgroup performance, clinician oversight and mechanisms to detect drift. The

central principle is that clinical AI must improve informed decisions, not create an opaque substitute

for professional judgment.

EVIDENCE / SOURCE CONTEXT

JMIR Perioperative Medicine (2026-10-01); narrative review; detailed results not available in supplied brief.

Expanded editorial analysis from a source brief; independent primary-source verification pending.

A R I S I N G H E A L T H / H E A L T H I N T E L L I G E N C E

SCIENCE, TECHNOLOGY & MEDICINE / FEATURE 15 OF 15

Whoop, Medicare and the Shift From Engagement to Outcomes

A wearable company is testing whether continuous health data can be tied to

measurable clinical improvement rather than subscriptions alone.

The supplied issue reports, citing STAT, that Whoop has entered Medicare’s ACCESS program, an

outcome-linked model for chronic-condition management. The described offering includes a wearable,

a 12-month app subscription and clinician access for eligible traditional Medicare patients. The

conditions discussed include hypertension, high cholesterol, obesity and prediabetes.

The most consequential detail is the payment logic. Consumer wearables traditionally succeed when

customers engage, renew and recommend the product. An outcomes-based program instead asks

whether blood pressure, hemoglobin A1c or LDL cholesterol improves or remains controlled. That

moves the commercial conversation from activity tracking toward clinically relevant endpoints.

There is a large gap between measuring a metric and improving it. The original article notes a

company-reported blood-pressure change without sufficient methods to judge causality or

generalizability. Wearable engagement may also be high without translating into improved health.

Clinician-facing summaries could help bridge that gap, but only if they are concise, validated and

actionable.

The regulatory boundary deserves attention. Features that estimate or interpret medical measures

may face a different level of scrutiny than wellness tracking. For patients, a wearable should

supplement rather than replace validated measurements and medical care. For health technology

companies, the next competitive advantage may be evidence of outcomes—not the number of data

points collected.

EVIDENCE / SOURCE CONTEXT

STAT coverage as described in the supplied issue, pp. 19–21; company/program claims require independent confirmation.

Expanded editorial analysis from a source brief; independent primary-source verification pending.